Bendroflumethiazide
As of the edition of 20 October 2026, Bendroflumethiazide is a small molecule: marketed, first approved in 1982 (US); acts on SLC12A3; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- NATURETIN-10
- First approved
- 1 January 1982 (US)
- Approvals on record
- 6 in 2 regions
- Holder of the most recent approval
- ETHYX PHARMACEUTICALS; 3 holders in all
- Registered trials
- 4, 0 stopped early
- Disease areas
- Heart and blood vessels; Infections; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC12A3 | Solute carrier family 12 member 3 | P55017 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Acquired holder and Earlier holder | 2003 to now |